2,614 results match your criteria Journal of thrombosis and thrombolysis[Journal]


De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis.

J Thromb Thrombolysis 2019 Apr 19. Epub 2019 Apr 19.

Department of Cardiology, LMU München, Marchioninistraße 15, 81377, Munich, Germany.

De-escalation from ticagrelor to clopidogrel in acute coronary syndrome (ACS) may occur for a variety of reasons, including side effects (bleeding and non-bleeding) and costs. This study sought to assess the prevalence of de-escalation from ticagrelor to clopidogrel and the occurrence of adverse clinical outcomes following de-escalation. We conducted a systematic review of clinical trials and real-world studies in ACS patients treated with ticagrelor. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-019-01860-7
Publisher Site
http://dx.doi.org/10.1007/s11239-019-01860-7DOI Listing
April 2019
1 Read

Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians.

J Thromb Thrombolysis 2019 Apr 19. Epub 2019 Apr 19.

Stonehill Professor of Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, CVC 4th Floor, Room 4936, Cincinnati, 45267, OH, USA.

Von Willebrand Factor (vWF) is a large glycoprotein with a broad range of physiological and pathological functions in health and disease. While vWF is critical for normal hemostasis, vascular integrity and repair, quantitative and qualitative abnormalities in the molecule can predispose to serious bleeding and thrombosis. The heritable form of von Willebrand Disease was first described nearly a century ago, but more recently, recognition of an acquired condition known as acquired von Willebrand Syndrome (AVWF) has emerged in persons with hematological, endocrine and cardiovascular diseases, disorders and conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01849-2DOI Listing

Use of oral anticoagulant drugs is associated with carotid intraplaque hemorrhage in atherosclerosis patients: a meta-analysis.

J Thromb Thrombolysis 2019 Apr 17. Epub 2019 Apr 17.

Department of Radiology, Huashan Hospital, Fudan University, No. 12 Wulumuqi Road (Middle), Shanghai, 200040, China.

Patients with carotid atherosclerosis, especially the elderly population, take antithrombotic medicine regularly. However, no previous meta-analysis has focused on one of the possible side effects of such drugs, namely intraplaque hemorrhage (IPH). To determine whether antiplatelet drugs or anticoagulants are associated with an increased risk of carotid IPH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01865-2DOI Listing

Exosome mediated differentiation of megakaryocytes: a study on TLR mediated effects.

J Thromb Thrombolysis 2019 Apr 16. Epub 2019 Apr 16.

Department of Biochemistry, School of Life Sciences, University of Hyderabad, (PO) Gachibowli, Hyderabad, TS, 500046, India.

Megakaryocytes are large polyploid bone marrow cells whose function is to produce circulatory platelets. Megakaryocytes are also known to release extracellular vesicles (EVs) of varying sizes. Toll like receptors (TLRs), present on the sentinel cells are essential components of the innate immune response, these receptors are also expressed by platelets and megakaryocytes. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-019-01862-5
Publisher Site
http://dx.doi.org/10.1007/s11239-019-01862-5DOI Listing
April 2019
1 Read

Drug-eluting stents versus bare-metal stents with a single month of dual antiplatelet therapy: a trial sequential analysis.

J Thromb Thrombolysis 2019 Apr 16. Epub 2019 Apr 16.

Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01861-6DOI Listing

The pleiotropic effect of rs7903146 on type 2 diabetes and ischemic stroke: a family-based study in a Chinese population.

J Thromb Thrombolysis 2019 Apr 12. Epub 2019 Apr 12.

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.

The rs7903146, an established genetic variant susceptible to type 2 diabetes (T2D), is also reported to be related to ischemic stroke (IS), though conflicting. Furthermore, it remained unknown whether the genetic association with stroke is independent of T2D. In the current study, 1603 individuals across 986 families were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01855-4DOI Listing

Increased coagulation factor XIII activity but not genetic variants of coagulation factors is associated with myocardial infarction in young patients.

J Thromb Thrombolysis 2019 Apr 10. Epub 2019 Apr 10.

Department of Cardiology, Medical Centre of Postgraduate Education, Grochowski Hospital, Grenadierow 51/59, 04-073, Warsaw, Poland.

The aim of the study was to investigate the possible role of coagulation factor XIII (FXIII) plasma activity and its gene (F13A1) Val34Leu variant as well as thrombospondin-2 gene (THBS2) T/G 3'UTR and thrombospondin-4 gene (THBS4) Ala387Pro variants in the development of myocardial infarction (MI) in young patients. The studied group consisted of 158 patients aged < 50 years with MI, and the control groups consisted of 150 healthy people aged < 50 years and 202 patients suffering from MI aged ≥ 50 years. Factor XIII activity was measured by photometric assay; genetic variants were determined using the restriction fragment length polymorphism (RFLP) method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01856-3DOI Listing
April 2019
1 Read

International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin.

J Thromb Thrombolysis 2019 Apr 10. Epub 2019 Apr 10.

Duke Clinical Research Institute, Durham, NC, 27705, USA.

We explored associations between INR measures and clinical outcomes in patients with AF using warfarin, and whether INR history predicted future INR measurements. We included patients in ARISTOTLE who were randomized to and received warfarin. Among patients who had events, we included those with ≥ 3 INR values in the 180 days prior to the event, with the most recent ≤ 60 days prior to the event, who were on warfarin at the time of event (n = 545). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01858-1DOI Listing
April 2019
1 Read

A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.

J Thromb Thrombolysis 2019 Apr 10. Epub 2019 Apr 10.

End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

A direct oral anticoagulant, edoxaban, is as effective as vitamin K antagonists for the treatment of venous thromboembolism (VTE). However, the mechanism underlying the treatment effect on VTE remains to be determined. The aims of this study were to evaluate the effect of edoxaban on tissue plasminogen activator (t-PA)-induced clot lysis in human plasma and to determine the roles of plasmin and thrombin-activatable fibrinolysis inhibitor (TAFI) in the profibrinolytic effect by edoxaban. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01851-8DOI Listing

Research Abstracts of the Anticoagulation Forum 15th National Conference on Anticoagulant Therapy.

Authors:

J Thromb Thrombolysis 2019 Apr 10. Epub 2019 Apr 10.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01850-9DOI Listing

Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia.

J Thromb Thrombolysis 2019 Apr 9. Epub 2019 Apr 9.

Department of Anesthesiology, Virginia Commonwealth University Health/Medical College of Virginia Hospitals, 1200 E. Broad Street, 7th Floor, P.O. Box 980695, Richmond, VA, 23298-0695, USA.

Drug-induced thrombocytopenia (DITP) has been described as a sudden and severe hematologic complication of piperacillin/tazobactam. The proposed mechanism by which piperacillin/tazobactam causes DITP involves the formation of a covalent bond to platelet membrane protein thereby inducing a humoral immune response. Given the immunogenic nature of this adverse event and the structural similarities across beta-lactam antibiotics, the potential for cross-reactivity between agents within the class should be considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01848-3DOI Listing
April 2019
3 Reads

Variation in platelet expression of FcγRIIa after myocardial infarction.

J Thromb Thrombolysis 2019 Apr 9. Epub 2019 Apr 9.

Departments of Medicine and Biochemistry, The University of Vermont, Burlington, VT, USA.

FcγRIIa amplifies platelet activation and greater platelet expression of FcγRIIa identifies patients at greater risk of subsequent cardiovascular events. Thus, platelet expression of FcγRIIa may be useful to guide therapy. Because platelet function tests are impacted by preparative procedures and substantial intra-individual variability, we examined the impact of these factors on platelet expression of FcγRIIa in blood from healthy subjects and in patients after myocardial infarction (MI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01852-7DOI Listing
April 2019
1 Read

Stroke prophylaxis in critically-ill patients with new-onset atrial fibrillation.

J Thromb Thrombolysis 2019 Apr 8. Epub 2019 Apr 8.

Department of Anesthesiology & Perioperative Medicine, Penn State Health Milton S. Hershey Medical Center, P.O Box 850, MC H187, Hershey, PA, 17033, USA.

Despite a high incidence of new onset atrial fibrillation (NOAF) in critically ill patients and its association with short and long-term incidence of stroke, there is limited data assessing anticoagulation on hospital discharge in these patients. We retrospectively reviewed electronic medical records of all adult patients admitted to non-cardiac ICUs at our institution between January 2009 and March 2016. Patients with NOAF were identified and CHADS-VASc score of ICU survivors was calculated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01854-5DOI Listing
April 2019
1 Read

Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review.

J Thromb Thrombolysis 2019 Apr 8. Epub 2019 Apr 8.

Department of Cardiology, Parkview Health, 11109 Parkview Plaza Drive, Fort Wayne, IN, 46845, USA.

Background: The International Society on Thrombosis and Haemostasis recommends avoiding the use of direct oral anticoagulants (DOACs) in patients with a body mass index (BMI) greater than 40 kg/m or weight greater than 120 kg.

Hypothesis: Higher BMI is associated with altered pharmacokinetics which may affect the safety and effectiveness for DOACs.

Methods: Data were collected on 3458 patients taking a DOAC prior to admission to a Midwestern health system between February 2013 and August 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01857-2DOI Listing

Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation.

J Thromb Thrombolysis 2019 Apr 6. Epub 2019 Apr 6.

University of Tsukuba School of Medicine, Ibaraki, Japan.

Anticoagulants are prescribed for prevention of thromboembolic events (TE) of atrial fibrillation (AF), however, their effects have a negative impact on disastrous bleeding outcomes. Idarucizumab was developed to reverse the anticoagulation effects of dabigatran. This study aimed to retrospectively investigate the clinical efficacy and safety of idarucizumab in the setting of progressive emergent bleeding events associated with catheter ablation (CA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01835-8DOI Listing
April 2019
3 Reads

The kallikrein-like activity of Heloderma venom is inhibited by carbon monoxide.

J Thromb Thrombolysis 2019 Apr 6. Epub 2019 Apr 6.

Mtoxins, 1111 Washington Ave, Oshkosh, WI, 54901, USA.

Lizards in the genus Heloderma are the most ancient venomous reptiles, with a traceable lineage nearly 100 million years old. The proteome of the venom of three of the remaining species (Heloderma suspectum, H. exasperatum, H. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01853-6DOI Listing
April 2019
1 Read

Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.

J Thromb Thrombolysis 2019 Apr 3. Epub 2019 Apr 3.

Princess Alexandra Hospital, Brisbane, Australia.

Current treatment dose of enoxaparin is based on total body weight (TBW), however dosage in obesity remains unclear. "Dose capping" commonly occurs if TBW > 100 kg minimising bleeding risk. However, this may result in under-dosing and increasing embolisation risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01847-4DOI Listing

Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.

J Thromb Thrombolysis 2019 Apr 2. Epub 2019 Apr 2.

Medical University of South Carolina, 150 Ashley Avenue, Charleston, SC, 29425, USA.

Oral factor Xa (fXa) inhibitor-related bleeding is a concerning drug safety problem. There is considerable controversy surrounding available reversal strategies. The recently approved reversal agent andexanet alfa has limited data, an unclear safety profile, and imparts a substantial financial burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01846-5DOI Listing
April 2019
3 Reads

Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry.

J Thromb Thrombolysis 2019 Mar 28. Epub 2019 Mar 28.

The Zena and Michael A. Wiener Cardiovascular Institute, The Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY, 10029-6574, USA.

We sought to investigate the utilization of prasugrel and its association with outcomes relative to clopidogrel in three typical subgroups of ACS in a real-world setting. Prasugrel is superior to clopidogrel for reducing risk of ischemic events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), but is associated with an increased risk of bleeding complications. PROMETHEUS was a retrospective multicenter observational study of 19,913 ACS patients undergoing PCI from 8 centers in the United States between 2010 and 2013. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-019-01842-9
Publisher Site
http://dx.doi.org/10.1007/s11239-019-01842-9DOI Listing
March 2019
5 Reads
2.039 Impact Factor

Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.

J Thromb Thrombolysis 2019 Mar 28. Epub 2019 Mar 28.

Pfizer Inc., New York, NY, USA.

Atrial fibrillation (AF) prevalence increases with age; > 80% of US adults with AF are aged ≥ 65 years. Compare the risk of stroke/systemic embolism (SE), major bleeding (MB), net clinical outcome (NCO), and major adverse cardiac events (MACE) among elderly non-valvular AF (NVAF) Medicare patients prescribed direct oral anticoagulants (DOACs) VS warfarin. NVAF patients aged ≥ 65 years who initiated DOACs (apixaban, dabigatran, and rivaroxaban) or warfarin were selected from 01JAN2013-31DEC2015 in CMS Medicare data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01838-5DOI Listing

Evaluation of heparin induced thrombocytopenia using probability scores in a mechanical circulatory support population.

J Thromb Thrombolysis 2019 Mar 27. Epub 2019 Mar 27.

Department of Pharmacy, Houston Methodist Hospital, 6565 Fannin St. DB1-09, Houston, TX, 77030, USA.

Patients on mechanical circulatory support (MCS) devices carry a high risk for thrombocytopenia and due to the routine use of heparin, heparin induced thrombocytopenia (HIT) is frequently suspected. HIT Expert Panel (HEP) and 4T scoring tools have been validated in the general medicine population to assess the probability of HIT diagnosis, however, these tests have not been validated for use in patients requiring MCS support. The objective of this study was to assess the association of 4T and HEP scores to available assess HIT diagnostic tests in patients requiring MCS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01843-8DOI Listing
March 2019
1 Read

Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients.

J Thromb Thrombolysis 2019 Mar 27. Epub 2019 Mar 27.

Department of Medical, Oral and Biotechnological Sciences, Gabriele D'Annunzio University, Chieti, Italy.

The long-term performance of prediction scores for venous thromboembolism (VTE) in cancer patients has been poorly investigated. We evaluated the discriminatory performance of the Khorana, PROTECHT, CONKO, and ONKOTEV scores for the first 3-6 months and for 12 months, and re-assessed scores after 3-6 months to determine the influence of variations in patients' risk classification on performance. Retrospective cohort of ambulatory patients with active cancer who were scheduled to receive first or new line of chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01845-6DOI Listing
March 2019
1 Read
2.039 Impact Factor

Exploring the structural similarity yet functional distinction between coagulation factor XIII-B and complement factor H sushi domains.

J Thromb Thrombolysis 2019 Mar 26. Epub 2019 Mar 26.

Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Sigmund Freud Str. 25, 53127, Bonn, Germany.

Coagulation factor XIII (FXIII) covalently crosslinks pre-formed fibrin clots preventing their premature fibrinolysis. In plasma, FXIII circulates as a zymogenic heterotetramer composed of catalytic FXIII-A subunits, and carrier/regulatory FXIII-B subunits. FXIII-A is a well characterized component of this complex, and has been associated with several pleiotropic roles outside coagulation as well. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01841-wDOI Listing
March 2019
1 Read

Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients.

J Thromb Thrombolysis 2019 Mar 22. Epub 2019 Mar 22.

Department of Surgery, Duke University Medical Center, 203 Research Drive, Suite 433, Box 2606, Durham, NC, 27710, USA.

Autologous adoptive T cell immunotherapy has been recognized as an effective treatment for cancer patients. The initial qualified lymphocytes is the core element determining the immunotherapeutic outcomes clinically. Cell separator based apheresis procedure is an optimal procedure to collect adequate mono-nucleated lymphocytes to generate efficient ex vivo T cell expansions; however, potential catheter-associated femoral vein thrombosis at post-apheresis might rise an additional deteriorated morbidity for cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01844-7DOI Listing
March 2019
1 Read

Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease.

J Thromb Thrombolysis 2019 Mar 16. Epub 2019 Mar 16.

Instituto do Coracao (InCor), Unidade de Coronariopatia Aguda, Hospital das Clinicas, Faculdade de Medicina (HCFMUSP), Universidade de Sao Paulo, São Paulo, Brazil.

Recent reports have suggested that aspirin effect might be influenced by bodyweight, with decreased efficacy in heavier individuals. We investigated the influence of bodyweight on aspirin pharmacodynamics in two independent datasets of patients taking non-enteric coated aspirin 100 mg QD for coronary artery disease (CAD). In the first dataset, 368 patients had their platelet aggregation assessed using VerifyNow Aspirin and measured in Aspirin Reaction Units (ARU). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01830-zDOI Listing

Management of Anticoagulation with Impella® Percutaneous Ventricular Assist Devices and Review of New Literature.

J Thromb Thrombolysis 2019 Mar 15. Epub 2019 Mar 15.

Department of Pharmacy, Houston Methodist Hospital, Houston, TX, USA.

Cardiogenic shock is a life-threatening condition that may occur secondary to a variety of cardiac conditions, and may require temporary support with percutaneous ventricular devices like the Impella®. Anticoagulation in patients with Impella® devices can often be complicated due to unpredictable purge flow rates, pre-existing coagulopathy, or heparin allergies. The purpose of this article is to discuss the various options for anticoagulation in the setting of Impella®. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01837-6DOI Listing
March 2019
2 Reads

Practice patterns of VTE chemoprophylaxis after discharge following hepatic and pancreatic resections for cancer: A survey of hepatopancreatobiliary surgeons.

J Thromb Thrombolysis 2019 Mar 15. Epub 2019 Mar 15.

National Institutes of Health, 10 Center Drive, Room 4W-3740, Bethesda, MD, 20892, USA.

Patients with hepatopancreatobiliary (HPB) malignancies undergoing resection are prone to venous thromboembolism (VTE), and current guidelines recommend up to 28 days of chemoprophylaxis after major surgery. We sought to determine the practice patterns among HPB surgeons for use of chemoprophylaxis after discharge. A survey on VTE chemoprophylaxis after oncologic HPB operations was distributed to attending surgeons at the 18 HPB fellowship training programs in the United States and Canada. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01834-9DOI Listing
March 2019
2 Reads

Leukoaraiosis is an independent predictor of intracranial hemorrhage in patients with atrial fibrillation.

J Thromb Thrombolysis 2019 Mar 14. Epub 2019 Mar 14.

Department of Life, Health & Environmental Sciences, University of L'Aquila, Piazzale S. Tommasi, Coppito- L'Aquila, Italy.

We evaluated the predictive value of several clinical, radiological and laboratory parameters on the risk of predict intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF). We conducted a case-control study on a consecutive hospital based series of patients with AF and ICH. A random sample of subjects with AF without ischemic or hemorrhagic stroke was selected from the same hospital in the same period to perform as the control group, with a ratio of two controls per case. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01839-4DOI Listing
March 2019
1 Read

Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.

J Thromb Thrombolysis 2019 Mar 11. Epub 2019 Mar 11.

Pfizer Inc, New York, NY, USA.

In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding. However, the relative benefit of LMWH versus VKA in patients with active cancer at high or low risk of rVTE and bleeding is unclear. This post hoc analysis used data from the CLOT study to explore the efficacy and safety of LMWH versus VKA in preventing recurrent thrombosis in high- and low-risk patients with active cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01833-wDOI Listing
March 2019
4 Reads

Highlights from the 2018 American Heart Association Scientific Sessions in Chicago, Illinois.

Authors:
Dylan L Steen

J Thromb Thrombolysis 2019 Mar 7. Epub 2019 Mar 7.

University of Cincinnati, Cincinnati, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01831-yDOI Listing

Thrombotic risk factors in patients with antiphospholipid syndrome: a single center experience.

J Thromb Thrombolysis 2019 Mar 5. Epub 2019 Mar 5.

Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, 1305 York Avenue 7th Floor, New York, NY, 10021, USA.

Patients with primary or secondary antiphospholipid syndrome (APS) have an increased risk of recurrent venous, arterial thrombosis and pregnancy complications. Therefore, determining thrombotic risk is important when individualizing antithrombotic therapy in patients with APS. To identify thrombotic risk factors in a cohort of APS patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01836-7DOI Listing
March 2019
4 Reads

Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation.

J Thromb Thrombolysis 2019 Mar 4. Epub 2019 Mar 4.

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece.

Scarce data are available on the effects of hospitalization on oral anticoagulation (OAC) patterns in patients with atrial fibrillation (AF). This study aimed to capture the evolving OAC patterns of patients with known non-valvular AF at high risk for stroke (CHADS-Vasc score ≥ 2 for males and ≥ 3 for females) during hospitalization. A total of 561 eligible patients who were admitted to the cardiology ward of a tertiary hospital were studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01832-xDOI Listing
March 2019
3 Reads

The rapid proliferation of solicited content online journals: a quest to disseminate knowledge?

J Thromb Thrombolysis 2019 Apr;47(3):337-344

Division of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati College of Medicine, Heart, Lung and Vascular Institute, Cincinnati, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01827-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471672PMC

Characterisation of acute ischemic stroke in patients with left ventricular thrombi after myocardial infarction.

J Thromb Thrombolysis 2019 Feb 25. Epub 2019 Feb 25.

Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore.

Acute ischemic stroke (AIS) is a feared complication in post-acute myocardial infarction (AMI) patients who develop left ventricular (LV) thrombus. There is limited data available on the incidence of stroke in this population, and characterisation of stroke subtypes has not been previously reported. Our study aims to evaluate the incidence of AIS in post-AMI patients with LV thrombus and to characterise the pattern of stroke subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01829-6DOI Listing
February 2019
2 Reads

Increased exercise-related platelet activation assessed by impedance aggregometry in diabetic patients despite aspirin therapy.

J Thromb Thrombolysis 2019 Apr;47(3):396-402

Department of Cardiology, Bursa Yuksek İhtisas Training and Research Hospital, Health Sciences University, Bursa, Turkey.

Aspirin is widely used for the prevention of thromboembolic diseases, but inhibition of platelet aggregation (PA) is not uniform. Additionally, aspirin has been shown to be ineffective in blunting PA in response to exercise in patients with coronary artery disease (CAD). Limited data exists about platelet function following acute exercise in diabetics taking aspirin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01825-wDOI Listing
April 2019
1 Read

Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.

J Thromb Thrombolysis 2019 Apr;47(3):345-352

Duke Heart Center, Duke Clinical Research Institute, Duke University School of Medicine, Box 3943 DUMC, Durham, NC, 27710, USA.

Warfarin is dependent on multiple hepatic enzymes for metabolism while apixaban is a substrate for P-glycoprotein (P-gp) transport and hepatic CYP3A4 metabolism. The aim of this analysis was to assess the impact of interacting medication use on the treatment effects of apixaban versus warfarin. Outcomes were compared between apixaban and warfarin using Cox proportional hazards modeling according to the use of interacting medications at randomization in ARISTOTLE (n = 18,201). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01823-yDOI Listing
April 2019
1 Read

Restenosis is associated with prothrombotic plasma fibrin clot characteristics in endovascularly treated patients with critical limb ischemia.

J Thromb Thrombolysis 2019 Feb 14. Epub 2019 Feb 14.

Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.

Introduction: Hypolysible fibrin clots composed of tightly packed fibers characterize patients with peripheral artery disease (PAD) especially those with critical limb ischemia (CLI). Little is known about the impact of a prothrombotic clot phenotype on restenosis following endovascular revascularization in CLI. The goal of this study was to compare fibrin clot properties and their determinants in CLI patients with restenosis after endovascular treatment (ET) and those free of this complication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01826-9DOI Listing
February 2019
3 Reads

Clinical implications of different risk factor profiles in patients with mesenteric venous thrombosis and systemic venous thromboembolism: a population-based study.

J Thromb Thrombolysis 2019 Feb 12. Epub 2019 Feb 12.

Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden.

It is unknown whether the risk factor profile for mesenteric venous thrombosis (MVT) is different from systemic venous thromboembolism (VTE). The aim of the present population-based study was to compare acquired and inherited risk factors in MVT versus VTE. Identification of all MVT patients at Skåne University Hospital between 2000 and 2015 was performed in patient records and AuriculA (Swedish anticoagulation registry). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01816-xDOI Listing
February 2019
1 Read

A clinical practice-based evaluation of the RIETE score in predicting occult cancer in patients with venous thromboembolism.

J Thromb Thrombolysis 2019 Feb 9. Epub 2019 Feb 9.

Department of Clinical Sciences, Danderyd Hospital, Division of Internal Medicine, Karolinska Institutet, Stockholm, Sweden.

The association between venous thromboembolism (VTE) and occult cancer is well established. However, the benefit of cancer screening in all VTE patients remains controversial. The Registro Informatizado Enfermedad TromboEmbólica (RIETE) score is a recently proposed risk score to identify VTE patients at high risk of occult cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01822-zDOI Listing
February 2019
3 Reads

Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial.

J Thromb Thrombolysis 2019 Apr;47(3):427-435

Department of Cardiology, LMU München, Munich, Germany.

To investigate the safety and efficacy of an early platelet function testing (PFT)-guided de-escalation of dual antiplatelet treatment (DAPT) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) with bioresorbable vascular scaffolds (BVS). Early DAPT de-escalation is a new non-inferior alternative to 12-months DAPT in patients with biomarker positive ACS treated with stent implantation. In this post-hoc analysis of the TROPICAL-ACS trial, which randomized 2610 ACS patients to a PFT-guided DAPT de-escalation (switch from prasugrel to clopidogrel) or to control group (uniform prasugrel), we compared clinical outcomes of patients (n = 151) who received a BVS during the index PCI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01811-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439143PMC
April 2019
2 Reads

Impact of time in therapeutic range after left ventricular assist device placement: a comparison between thrombus and thrombus-free periods.

J Thromb Thrombolysis 2019 Apr;47(3):361-368

Advanced Heart Failure, Sentara Norfolk General Hospital, Norfolk, VA, USA.

The association between time in therapeutic range (TTR) and clinical outcomes in patients with left ventricular assist devices (LVADs) on chronic warfarin therapy is not well understood. This study assessed TTR using the Rosendaal Method prior to suspected or confirmed pump thrombosis or ischemic stroke. Each patient served as their own control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-01800-xDOI Listing
April 2019
2 Reads

Impaired endogenous fibrinolysis at high shear using a point-of-care test in STEMI is associated with alterations in clot architecture.

J Thromb Thrombolysis 2019 Apr;47(3):392-395

Postgraduate Medical School, University of Hertfordshire, Hertfordshire, UK.

Impaired endogenous fibrinolysis is an adverse prognostic biomarker in acute coronary syndrome (ACS). Abnormally dense in vitro fibrin thrombi have been demonstrated in ACS patients and related to hypofibrinolysis using cumbersome, laboratory-based methods. We aimed to assess endogenous fibrinolysis using a point-of-care technique and relate this to clot architecture. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-01799-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439169PMC
April 2019
1 Read

The value of sPESI for risk stratification in patients with pulmonary embolism.

J Thromb Thrombolysis 2019 Feb 7. Epub 2019 Feb 7.

Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

Introduction: Various risk stratification methods exist for patients with pulmonary embolism (PE). We used the simplified Pulmonary Embolism Severity Index (sPESI) as a risk-stratification method to understand the Veterans Health Administration (VHA) PE population.

Materials And Methods: Adult patients with ≥ 1 inpatient PE diagnosis (index date = discharge date) from October 2011-June 2015 as well as continuous enrollment for ≥ 12 months pre- and 3 months post-index date were included. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-019-01814-z
Publisher Site
http://dx.doi.org/10.1007/s11239-019-01814-zDOI Listing
February 2019
5 Reads
2.039 Impact Factor

Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.

J Thromb Thrombolysis 2019 Apr;47(3):384-391

Department of Otolaryngology, Head/Neck & Facial Plastic Surgery, Sana Kliniken Leipziger Land, Rudolf-Virchow-Strasse 2, 04552, Borna, Germany.

Patients taking oral anticoagulants (OACs) currently represent one-third of all patients treated for epistaxis and an upward trend is expected. New direct oral anticoagulants (DOACs) have been on the market for approximately 10 years. DOACs are favoured over Vitamin K-Antagonists (VKAs) in the current guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01824-xDOI Listing

Thrombin generation profile in non-thrombotic factor V Leiden carriers.

J Thromb Thrombolysis 2019 Apr;47(3):473-477

Normandie Univ, UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit, F 76000, Rouen, France.

Factor V Leiden (FVL) mutation is the most common genetic risk factor for venous thromboembolism. In families with a history of thrombosis, FVL can be present in 18%. Thrombin generation test is commonly used as an evaluation tool of thrombotic risk. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-019-01821-0
Publisher Site
http://dx.doi.org/10.1007/s11239-019-01821-0DOI Listing
April 2019
10 Reads

Highlights from the 2018 European Society of Cardiology Congress in Munich, Germany.

Authors:
Dylan L Steen

J Thromb Thrombolysis 2019 Feb;47(2):312-315

University of Cincinnati, Cincinnati, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01810-3DOI Listing
February 2019

Body mass index reduction improves the baseline procoagulant imbalance of obese subjects.

J Thromb Thrombolysis 2019 Jan 30. Epub 2019 Jan 30.

IRCCS Cà Granda Maggiore Hospital Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi villa, Via Pace 9, 20122, Milano, Italy.

Obesity is a risk factor for cardiovascular diseases. The latter being dependent (at least in part) on plasma procoagulant imbalance (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01818-9DOI Listing
January 2019

Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period.

J Thromb Thrombolysis 2019 Apr;47(3):481-485

Department of Medicine, University of Padua Medical School, Via Ospedale, 105, 35128, Padua, Italy.

To investigate the occurrence of thrombotic events (myocardial infarction, deep vein thrombosis or ischemic stroke) in a group of 39 cases of severe FXII deficiency during a mean 22.5 years follow-up. All patients seen in Padua during the years 1968-2006 will the object of this investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01819-8DOI Listing
April 2019
2 Reads

The comparative analysis of non-thrombotic internal jugular vein stenosis and cerebral venous sinus stenosis.

J Thromb Thrombolysis 2019 Jan 28. Epub 2019 Jan 28.

Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.

Internal jugular vein (IJV) stenosis and cerebral venous sinus (CVS) stenosis belong to cerebral venous outflow insufficiency. This study aimed to analyze the similarities and differences between IJV stenosis and CVS stenosis. Patients with either IJV stenosis or CVS stenosis confirmed by contrast-enhanced magnetic resonance venography between October 2017 and July 2018 were enrolled in this retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01820-1DOI Listing
January 2019
2.039 Impact Factor